Screener
PTC Therapeutics PTCT Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Acquisition of product rights and licenses | (156) | (808) |
| Net cash used in investing activities | $(93,736) | $(184,360) |
| Cash flows from financing activities | ||
| Proceeds from exercise of options | $6,403 | $15,751 |
| Payments on contingent consideration obligation | — | (6,341) |
| Net cash provided by financing activities | $6,403 | $9,410 |
| Effect of exchange rate changes on cash | (1,524) | 5,393 |
| Net (decrease) increase in cash and cash equivalents | (147,899) | 700,546 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's stock issuance proceeds?
- PTC Therapeutics (PTCT) reported stock issuance proceeds of $6.4M in Q1 2026.
- How has PTC Therapeutics's stock issuance proceeds changed year-over-year?
- PTC Therapeutics's stock issuance proceeds decreased by 59.3% year-over-year, from $15.75M to $6.4M.
- What is the long-term trend for PTC Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), PTC Therapeutics's stock issuance proceeds has grown at a 52.3% compound annual growth rate (CAGR), from $17.31M to $93.1M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about PTC Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude